Silver Book Fact

According to the National Institutes of Health, use of the clot-busting drug t-PA saves $4,400 per patient in hospitalization and nursing home costs.

Houston K. Innovative Drugs Cost Patients Less in the Long Run. Chicago Sun Times. 30-Jul-2004

Reference

Title
Innovative Drugs Cost Patients Less in the Long Run
Publication
Chicago Sun Times
Publication Date
30-Jul-2004
Authors
Houston K

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • If all forms of cardiovascular disease were eliminated, life expectancy would rise by almost 7 years.  
  • Without antihypertensive therapies, blood pressures (at age 40+) would have been between 10% and 13% higher in 1999-2000. Additionally, 86,000 excess premature deaths from cardiovascular disease would have occurred in…  
  • Pioglitazone associated with relative risk reduction in recurrent stroke
    The PROactive trial to manage glucose in diabetics with a history of cardiovascular disease, stroke, or other vascular risk factors found that treatment with pioglitazone was associated with a 47% relative…  
  • In the 1980s, approximately 400,000 major infarctions were occurring each year in the U.S. and 40% of patients were dying within the first year. 1-year mortality is now 4-8%.  
  • A recent data analysis of more than 2,700 stroke patients from the U.S. and Europe confirmed tPA’s effectiveness, which could save the U.S. nearly $50 million a year.